Lakewood-Amedex Biotherapeutics Says It Obtained IRB Approvals, Site Readiness To Begin Phase 2a Trial Of Nu-3 In Infected Diabetic Foot Ulcers
Share
Why It Matters
Lakewood-Amedex got permission to test a new medicine on diabetic foot wounds. This is an early step forward that shows the company is making real progress.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.